Consumer health company Kenvue Inc. (NYSE:KVUE) stock is trading higher after the company reported better-than-expected second-quarter 2024 financial results. The Johnson & Johnson consumer spin-off reported sales of $4 billion, down 0.3% year-over-year (up 1.5% organically), beating the consensus of $3.94 billion. Kenvue’s some of the iconic brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. Value realization was driven by carry-over pricing and new price actions. The slight volume declines were driven primarily by Skin Health and Beauty and Self Care, partially offset by growth in Essential Health. Adjusted gross profit margin expanded 410 basis points to 61.6% ...